| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.57 | 0.01 | 0.57 | Calpain 2 inhibitor | |||
| 0.503 | 0.074 | 0.503 | Transcription factor inhibitor | |||
| 0.444 | 0.054 | 0.444 | Calcium channel L-type activator | 0.395 0.085 DBMET00249 | ||
| 0.36 | 0.005 | 0.416 | Androgen antagonist | 0.416 0.004 DBMET00249 | DBMET00249 | |
| 0.43 | 0.076 | 0.43 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.338 0.164 DBMET00249 | ||
| 0.417 | 0.067 | 0.417 | Histamine release inhibitor | |||
| 0.327 | 0.041 | 0.327 | Transcription factor STAT3 inhibitor | |||
| 0.275 | 0.005 | 0.275 | Potassium channel activator | 0.215 0.007 DBMET00249 | ||
| 0.297 | 0.031 | 0.297 | Calpain inhibitor | |||
| 0.309 | 0.051 | 0.309 | Transcription factor STAT inhibitor | |||
| 0.285 | 0.027 | 0.285 | Neuropeptide Y2 antagonist | |||
| 0.384 | 0.126 | 0.384 | DNA polymerase beta inhibitor | |||
| 0.381 | 0.123 | 0.468 | Caspase 9 stimulant | 0.468 0.074 DBMET00249 | DBMET00249 | |
| 0.255 | 0.008 | 0.255 | Catalase inhibitor | 0.087 0.044 DBMET00249 | ||
| 0.307 | 0.069 | 0.307 | Interleukin 2 agonist | |||
| 0.303 | 0.078 | 0.303 | 12-Lipoxygenase inhibitor | 0.185 0.168 DBMET00249 | ||
| 0.226 | 0.005 | 0.226 | Prostaglandin-E synthase inhibitor | 0.151 0.011 DBMET00249 | ||
| 0.223 | 0.004 | 0.223 | NMDA receptor agonist | 0.095 0.021 DBMET00249 | ||
| 0.251 | 0.032 | 0.251 | Amyloid beta precursor protein antagonist | |||
| 0.335 | 0.129 | 0.335 | 5 Hydroxytryptamine release inhibitor | |||
| 0.344 | 0.139 | 0.344 | Alpha-glucosidase inhibitor | |||
| 0.344 | 0.14 | 0.344 | DNA directed DNA polymerase inhibitor | |||
| 0.232 | 0.035 | 0.232 | 3C-like protease (Human coronavirus) inhibitor | |||
| 0.198 | 0.003 | 0.198 | NMDA receptor glycine site agonist | 0.117 0.01 DBMET00249 | ||
| 0.297 | 0.104 | 0.297 | Thioredoxin glutathione reductase inhibitor | |||
| 0.314 | 0.129 | 0.314 | Beta lactamase inhibitor | |||
| 0.196 | 0.013 | 0.196 | Sphingosine 1-phosphate receptor 5 antagonist | 0.137 0.085 DBMET00249 | ||
| 0.228 | 0.051 | 0.228 | Nitric-oxide synthase stimulant | 0.198 0.092 DBMET00249 | ||
| 0.214 | 0.039 | 0.214 | Succinate dehydrogenase inhibitor | 0.193 0.054 DBMET00249 | ||
| 0.179 | 0.005 | 0.238 | Androgen agonist | 0.238 0.004 DBMET00249 | DBMET00249 | |
| 0.265 | 0.094 | 0.265 | Streptokinase A inhibitor | |||
| 0.272 | 0.104 | 0.272 | Thyroid hormone beta antagonist | |||
| 0.279 | 0.113 | 0.33 | Calcium channel activator | 0.33 0.064 DBMET00249 | DBMET00249 | |
| 0.273 | 0.109 | 0.273 | Thyroid hormone antagonist | |||
| 0.237 | 0.082 | 0.237 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.163 0.127 DBMET00249 | ||
| 0.186 | 0.038 | 0.186 | M17 leucyl aminopeptidase inhibitor | |||
| 0.189 | 0.044 | 0.189 | Thiol protease inhibitor | |||
| 0.145 | 0.003 | 0.145 | Dihydroorotate oxidase inhibitor | 0.073 0.015 DBMET00249 | ||
| 0.179 | 0.037 | 0.202 | CF transmembrane conductance regulator agonist | 0.202 0.02 DBMET00249 | DBMET00249 | |
| 0.139 | 0.005 | 0.139 | Glutamate (mGluR group III) agonist | |||
| 0.225 | 0.093 | 0.225 | Superoxide dismutase inhibitor | 0.212 0.105 DBMET00249 | ||
| 0.16 | 0.029 | 0.16 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.156 | 0.026 | 0.156 | Potassium channel (Ca-activated) activator | 0.112 0.046 DBMET00249 | ||
| 0.231 | 0.103 | 0.231 | Gastrin inhibitor | 0.184 0.173 DBMET00249 | ||
| 0.156 | 0.028 | 0.156 | Sphingosine 1-phosphate receptor 4 antagonist | 0.125 0.064 DBMET00249 | ||
| 0.151 | 0.023 | 0.151 | Urease inhibitor | 0.148 0.024 DBMET00249 | ||
| 0.141 | 0.016 | 0.141 | Potassium channel (Voltage-sensitive) activator | |||
| 0.15 | 0.027 | 0.15 | CDK3/cyclin E inhibitor | |||
| 0.212 | 0.096 | 0.212 | Aryl hydrocarbon receptor agonist | |||
| 0.156 | 0.042 | 0.156 | Cathepsin H inhibitor | |||
| 0.141 | 0.035 | 0.141 | Caspase 3 inhibitor | |||
| 0.171 | 0.066 | 0.171 | Death-associated protein kinase 2 inhibitor | |||
| 0.136 | 0.034 | 0.168 | UDP-glucose 4-epimerase inhibitor | 0.168 0.024 DBMET00249 | DBMET00249 | |
| 0.209 | 0.113 | 0.209 | Interleukin agonist | 0.164 0.154 DBMET00249 | ||
| 0.184 | 0.089 | 0.184 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.097 | 0.004 | 0.097 | NMDA receptor glycine site antagonist | 0.038 0.009 DBMET00249 | ||
| 0.137 | 0.044 | 0.137 | Aminopeptidase B inhibitor | |||
| 0.142 | 0.052 | 0.142 | Death-associated protein kinase 1 inhibitor | |||
| 0.101 | 0.011 | 0.101 | Dihydroorotate dehydrogenase inhibitor | 0.049 0.038 DBMET00249 | ||
| 0.115 | 0.026 | 0.115 | Glutathione S-transferase inhibitor | 0.081 0.059 DBMET00249 | ||
| 0.127 | 0.041 | 0.127 | Falcipain inhibitor | |||
| 0.125 | 0.04 | 0.125 | Falcipain 2 inhibitor | |||
| 0.118 | 0.033 | 0.211 | Triose-phosphate isomerase inhibitor | 0.211 0.01 DBMET00249 | DBMET00249 | |
| 0.096 | 0.011 | 0.096 | Exportin-1 inhibitor | 0.077 0.029 DBMET00249 | ||
| 0.165 | 0.084 | 0.165 | LIM domain kinase 1 inhibitor | |||
| 0.085 | 0.005 | 0.085 | Glutamate (mGluR4) agonist | |||
| 0.086 | 0.006 | 0.086 | Potassium channel (Inward rectifier) activator | 0.077 0.009 DBMET00249 | ||
| 0.088 | 0.009 | 0.088 | Kainate receptor antagonist | 0.045 0.024 DBMET00249 | ||
| 0.083 | 0.006 | 0.083 | Potassium channel (ATP-sensitive) activator | 0.074 0.008 DBMET00249 | ||
| 0.142 | 0.068 | 0.142 | Pregnane X receptor agonist | 0.137 0.08 DBMET00249 | ||
| 0.086 | 0.013 | 0.086 | Sphingosine 1-phosphate receptor 3 antagonist | |||
| 0.107 | 0.035 | 0.107 | Bcr-Abl kinase inhibitor | |||
| 0.096 | 0.024 | 0.096 | Sphingosine 1-phosphate receptor antagonist | |||
| 0.096 | 0.025 | 0.096 | Potassium channel large-conductance Ca-activated activator | 0.08 0.035 DBMET00249 | ||
| 0.113 | 0.043 | 0.113 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.111 0.045 DBMET00249 | ||
| 0.074 | 0.004 | 0.074 | Glutamate (mGluR8) agonist | 0.073 0.005 DBMET00249 | ||
| 0.103 | 0.034 | 0.103 | Vanilloid antagonist | |||
| 0.138 | 0.07 | 0.138 | Calcium channel blocker | |||
| 0.215 | 0.147 | 0.215 | Prostaglandin dehydrogenase inhibitor | |||
| 0.115 | 0.048 | 0.154 | Adenylate kinase inhibitor | 0.154 0.025 DBMET00249 | DBMET00249 | |
| 0.156 | 0.091 | 0.156 | ATPase inhibitor | |||
| 0.09 | 0.031 | 0.09 | Vanilloid 1 antagonist | |||
| 0.117 | 0.06 | 0.117 | Calcium channel (voltage-sensitive) blocker | |||
| 0.067 | 0.011 | 0.067 | Collagenase inhibitor | |||
| 0.08 | 0.025 | 0.08 | NMDA 2C receptor antagonist | 0.057 0.049 DBMET00249 | ||
| 0.137 | 0.086 | 0.137 | Neuropeptide Y1 antagonist | |||
| 0.098 | 0.049 | 0.098 | Calcium antagonist | |||
| 0.059 | 0.011 | 0.059 | Delayed rectifier potassium channel activator | |||
| 0.059 | 0.011 | 0.059 | Potassium channel KCNQ activator | |||
| 0.09 | 0.045 | 0.09 | D-Ala-D-Ala ligase inhibitor | |||
| 0.149 | 0.105 | 0.149 | Neurotensin receptor agonist | |||
| 0.088 | 0.044 | 0.094 | Thioredoxin reductase inhibitor | 0.094 0.035 DBMET00249 | DBMET00249 | |
| 0.058 | 0.015 | 0.058 | Glutamate (mGluR4) antagonist | 0.043 0.031 DBMET00249 | ||
| 0.101 | 0.059 | 0.149 | Creatine kinase inhibitor | 0.149 0.024 DBMET00249 | DBMET00249 | |
| 0.098 | 0.057 | 0.098 | Interleukin 12 antagonist | |||
| 0.052 | 0.012 | 0.052 | Potassium channel Kv1.1 blocker | |||
| 0.063 | 0.024 | 0.063 | Glycine transporter 2 inhibitor | |||
| 0.07 | 0.032 | 0.101 | Biliverdin reductase inhibitor | 0.101 0.018 DBMET00249 | DBMET00249 | |
| 0.053 | 0.015 | 0.06 | Nerve growth factor antagonist | 0.06 0.01 DBMET00249 | DBMET00249 | |
| 0.099 | 0.063 | 0.133 | Anabolic | 0.133 0.029 DBMET00249 | DBMET00249 | |
| 0.078 | 0.042 | 0.078 | Calcium channel L-type blocker | |||
| 0.202 | 0.167 | 0.202 | Transcription factor NF kappa B inhibitor | |||
| 0.078 | 0.044 | 0.078 | Epoxide hydrolase inhibitor | |||
| 0.048 | 0.015 | 0.048 | Glucagon-like peptide 1 receptor antagonist | |||
| 0.039 | 0.007 | 0.039 | Kainate receptor 1 antagonist | |||
| 0.048 | 0.017 | 0.048 | Kainate receptor 2 antagonist | |||
| 0.033 | 0.004 | 0.077 | Progesterone receptor B antagonist | 0.077 0.002 DBMET00249 | DBMET00249 | |
| 0.041 | 0.013 | 0.045 | Catechol O-methyltransferase inhibitor | 0.045 0.011 DBMET00249 | DBMET00249 | |
| 0.049 | 0.021 | 0.058 | CDK5/p25 inhibitor | 0.058 0.016 DBMET00249 | DBMET00249 | |
| 0.055 | 0.027 | 0.055 | Plasminogen activator inhibitor antagonist | |||
| 0.062 | 0.035 | 0.107 | Argininosuccinate synthase inhibitor | 0.107 0.017 DBMET00249 | DBMET00249 | |
| 0.076 | 0.05 | 0.076 | Vanilloid 4 agonist | |||
| 0.195 | 0.169 | 0.238 | Cholesterol antagonist | 0.238 0.134 DBMET00249 | DBMET00249 | |
| 0.122 | 0.097 | 0.197 | Mannose-6-phosphate isomerase inhibitor | 0.197 0.032 DBMET00249 | DBMET00249 | |
| 0.074 | 0.049 | 0.074 | Metalloproteinase-9 inhibitor | |||
| 0.066 | 0.042 | 0.066 | Neuraminidase (influenza) inhibitor | |||
| 0.097 | 0.074 | 0.097 | Ferrochelatase inhibitor | |||
| 0.132 | 0.108 | 0.132 | Heat shock protein 90 alpha antagonist | |||
| 0.104 | 0.081 | 0.104 | TRPA1 agonist | 0.096 0.095 DBMET00249 | ||
| 0.062 | 0.039 | 0.062 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.11 | 0.088 | 0.11 | Alpha-N-acetylglucosaminidase inhibitor | 0.103 0.097 DBMET00249 | ||
| 0.083 | 0.061 | 0.083 | 3C-Like protease (SARS coronavirus) inhibitor | |||
| 0.116 | 0.096 | 0.116 | Vanilloid 1 agonist | |||
| 0.064 | 0.044 | 0.083 | Transcription factor RelA inhibitor | 0.083 0.015 DBMET00249 | DBMET00249 | |
| 0.12 | 0.1 | 0.12 | Cytidine deaminase inhibitor | |||
| 0.028 | 0.009 | 0.028 | Protease (Human cytomegalovirus) inhibitor | |||
| 0.026 | 0.007 | 0.026 | Factor XIII inhibitor | |||
| 0.072 | 0.053 | 0.072 | Nav1.8 sodium channel blocker | |||
| 0.186 | 0.168 | 0.186 | MAP kinase kinase 3 inhibitor | |||
| 0.092 | 0.074 | 0.092 | Nitric-oxide synthase inhibitor | |||
| 0.035 | 0.017 | 0.035 | AMPA 1 receptor antagonist | |||
| 0.098 | 0.081 | 0.109 | DOPA decarboxylase inhibitor | 0.109 0.06 DBMET00249 | DBMET00249 | |
| 0.059 | 0.042 | 0.059 | Ca(v)3.2 blocker | |||
| 0.023 | 0.006 | 0.025 | Potassium channel (Inward rectifier) 11 blocker | 0.025 0.005 DBMET00249 | DBMET00249 | |
| 0.075 | 0.058 | 0.075 | Metalloproteinase-2 inhibitor | |||
| 0.058 | 0.041 | 0.058 | Cathepsin L inhibitor | |||
| 0.044 | 0.029 | 0.044 | Carbonic anhydrase IV inhibitor | |||
| 0.026 | 0.011 | 0.026 | Kainate receptor 5 antagonist | 0.02 0.015 DBMET00249 | ||
| 0.059 | 0.044 | 0.059 | Neuraminidase inhibitor | |||
| 0.08 | 0.065 | 0.08 | CC chemokine 5 receptor agonist | |||
| 0.085 | 0.071 | 0.085 | HIV-1 integrase (Overall Integration) inhibitor | |||
| 0.101 | 0.087 | 0.101 | Interleukin 2 antagonist | |||
| 0.044 | 0.031 | 0.044 | Dihydroorotase inhibitor | |||
| 0.027 | 0.015 | 0.027 | Kainate receptor 4 antagonist | 0.023 0.019 DBMET00249 | ||
| 0.032 | 0.022 | 0.032 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.06 | 0.051 | 0.06 | Neutrophil collagenase inhibitor | |||
| 0.055 | 0.046 | 0.055 | Botulinum neurotoxin type A inhibitor | |||
| 0.037 | 0.028 | 0.037 | TRPM8 blocker | |||
| 0.068 | 0.059 | 0.09 | Glutamate dehydrogenase inhibitor | 0.09 0.037 DBMET00249 | DBMET00249 | |
| 0.078 | 0.069 | 0.078 | NMDA receptor antagonist | 0.075 0.072 DBMET00249 | ||
| 0.045 | 0.036 | 0.045 | AMPA receptor antagonist | |||
| 0.015 | 0.006 | 0.015 | Human herpes virus 5 capsid protein P40 inhibitor | |||
| 0.11 | 0.101 | 0.11 | Interleukin 4 antagonist | |||
| 0.115 | 0.107 | 0.146 | Cell wall synthesis inhibitor | 0.146 0.07 DBMET00249 | DBMET00249 | |
| 0.02 | 0.013 | 0.02 | 5-Alpha-reductase 2 inhibitor | |||
| 0.034 | 0.027 | 0.034 | Nicotinic acid receptor agonist | |||
| 0.059 | 0.052 | 0.059 | Histone deacetylase SIRT3 inhibitor | |||
| 0.047 | 0.041 | 0.047 | Lysophosphatidic acid 3 receptor antagonist | |||
| 0.04 | 0.035 | 0.04 | NMDA receptor subunit 3B antagonist | |||
| 0.029 | 0.024 | 0.029 | Cyclophilin A inhibitor | |||
| 0.069 | 0.064 | 0.069 | GABA aminotransferase inhibitor | |||
| 0.041 | 0.037 | 0.041 | Glutamate (mGluR group III) antagonist | |||
| 0.025 | 0.022 | 0.027 | NMDA 2D receptor antagonist | 0.027 0.019 DBMET00249 | DBMET00249 | |
| 0.047 | 0.044 | 0.047 | CD45 antagonist | |||
| 0.18 | 0.177 | 0.181 | Tyrosine 3 hydroxylase inhibitor | 0.181 0.175 DBMET00249 | DBMET00249 | |
| 0.028 | 0.026 | 0.028 | Epoxide hydrolase 1 inhibitor | |||
| 0.048 | 0.046 | 0.048 | Acetyl-CoA transferase inhibitor | |||
| 0.099 | 0.097 | 0.099 | Calcium channel N-type blocker | |||
| 0.011 | 0.01 | 0.013 | Glutamate (mGluR6) agonist | 0.013 0.007 DBMET00249 | DBMET00249 | |
| 0.046 | 0.045 | 0.046 | Neuropeptide agonist | |||
| 0.015 | 0.014 | 0.015 | Kainate receptor 3 antagonist | |||
| 0.145 | 0.146 | 0.149 | Neurotrophic factor enhancer | 0.149 0.14 DBMET00249 | DBMET00249 | |
| 0.046 | 0.05 | 0.083 | Alcohol oxidase inhibitor | 0.083 0.023 DBMET00249 | DBMET00249 | |
| 0.059 | 0.069 | 0.111 | Porphobilinogen synthase inhibitor | 0.111 0.031 DBMET00249 | DBMET00249 | |
| 0.067 | 0.081 | 0.074 | GABA B receptor agonist | 0.074 0.057 DBMET00249 | DBMET00249 | |
| 0.049 | 0.066 | 0.066 | Purinergic P2X1 antagonist | 0.066 0.036 DBMET00249 | DBMET00249 | |
| 0.023 | 0.04 | 0.032 | Progesterone antagonist | 0.032 0.027 DBMET00249 | DBMET00249 | |
| 0.12 | 0.15 | 0.158 | Anesthetic general | 0.158 0.106 DBMET00249 | DBMET00249 | |
| 0.124 | 0.158 | 0.14 | Ca2+-transporting ATPase inhibitor | 0.14 0.075 DBMET00249 | DBMET00249 | |
| 0.044 | 0.079 | 0.098 | Phosphofructokinase-1 inhibitor | 0.098 0.032 DBMET00249 | DBMET00249 | |
| 0.045 | 0.091 | 0.071 | Histidine decarboxylase inhibitor | 0.071 0.05 DBMET00249 | DBMET00249 | |
| 0.078 | 0.156 | 0.101 | Factor V inhibitor | 0.101 0.067 DBMET00249 | DBMET00249 | |
| 0.178 | 0.258 | 0.332 | Antibacterial | 0.332 0.113 DBMET00249 | DBMET00249 | |
| 0.013 | 0.097 | 0.031 | Fumarate hydratase inhibitor | 0.031 0.027 DBMET00249 | DBMET00249 | |
| 0.133 | 0.231 | 0.183 | MAP kinase kinase 5 inhibitor | 0.183 0.058 DBMET00249 | DBMET00249 | |
| 0.058 | 0.162 | 0.098 | Lanosterol 14 alpha demethylase inhibitor | 0.098 0.058 DBMET00249 | DBMET00249 | |
| 0.06 | 0.174 | 0.121 | AMP-activated protein kinase stimulant | 0.121 0.048 DBMET00249 | DBMET00249 | |
| 0.046 | 0.172 | 0.061 | Calcium channel P-type blocker | 0.061 0.056 DBMET00249 | DBMET00249 | |
| 0.026 | 0.271 | 0.113 | Epidermal growth factor antagonist | 0.113 0.036 DBMET00249 | DBMET00249 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |